Calamos Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$4,903,450
+22.6%
5,000,0000.0%0.02%
+25.0%
Q2 2023$3,998,350
-3.8%
5,000,0000.0%0.02%0.0%
Q1 2023$4,156,550
+9.8%
5,000,0000.0%0.02%
+11.1%
Q4 2022$3,784,450
+0.2%
5,000,0000.0%0.02%
+5.9%
Q3 2022$3,777,000
+17.7%
5,000,0000.0%0.02%
+21.4%
Q2 2022$3,209,000
+4.6%
5,000,0000.0%0.01%
+16.7%
Q1 2022$3,068,000
+1.9%
5,000,0000.0%0.01%
+9.1%
Q4 2021$3,012,000
-0.6%
5,000,0000.0%0.01%
-15.4%
Q3 2021$3,030,000
-11.4%
5,000,0000.0%0.01%
-18.8%
Q2 2021$3,421,000
+6.2%
5,000,0000.0%0.02%
-11.1%
Q1 2021$3,220,000
+6.1%
5,000,0000.0%0.02%0.0%
Q4 2020$3,036,000
-12.4%
5,000,0000.0%0.02%
-18.2%
Q3 2020$3,465,000
-3.8%
5,000,0000.0%0.02%
-12.0%
Q2 2020$3,602,000
-17.1%
5,000,0000.0%0.02%
-26.5%
Q1 2020$4,345,000
-34.7%
5,000,0000.0%0.03%
+3.0%
Q4 2019$6,649,000
+46.6%
5,000,0000.0%0.03%
+32.0%
Q3 2019$4,537,000
-9.2%
5,000,0000.0%0.02%
-10.7%
Q2 2019$4,998,0005,000,0000.03%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 55,943,000$34,742,0001.33%
PenderFund Capital Management Ltd. 5,000,000$3,839,0000.98%
Context Capital Management, LLC 7,485,000$4,494,0000.62%
Opti Capital Management, LP 7,000,000$4,250,0000.47%
Soros Fund Management 32,298,000$19,611,0000.37%
Shaolin Capital Management LLC 7,000,000$4,175,0000.29%
Weiss Asset Management LP 3,500,000$2,084,0000.09%
CSS LLC/IL 2,825,000$1,681,0000.06%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$137,0000.02%
LAZARD ASSET MANAGEMENT LLC 25,000,000$15,009,0000.02%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders